Gilead Sciences, Inc. (NASDAQ:GILD) Position Increased by Factorial Partners LLC

Factorial Partners LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 16.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,300 shares of the biopharmaceutical company’s stock after buying an additional 3,000 shares during the quarter. Factorial Partners LLC’s holdings in Gilead Sciences were worth $1,314,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership lifted its stake in Gilead Sciences by 324.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after buying an additional 13,764,169 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Gilead Sciences by 70.6% in the first quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after purchasing an additional 6,410,047 shares in the last quarter. Northern Trust Corp lifted its position in shares of Gilead Sciences by 2.3% in the second quarter. Northern Trust Corp now owns 15,313,169 shares of the biopharmaceutical company’s stock worth $946,506,000 after purchasing an additional 343,918 shares in the last quarter. Parnassus Investments LLC lifted its position in shares of Gilead Sciences by 8.1% in the second quarter. Parnassus Investments LLC now owns 11,720,556 shares of the biopharmaceutical company’s stock worth $724,448,000 after purchasing an additional 880,418 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in shares of Gilead Sciences by 9.1% in the second quarter. Deutsche Bank AG now owns 8,950,346 shares of the biopharmaceutical company’s stock worth $553,222,000 after purchasing an additional 746,049 shares in the last quarter. 78.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on GILD shares. Bank of America reissued a “neutral” rating and issued a $85.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 13th. Robert W. Baird raised their price objective on shares of Gilead Sciences to $69.00 in a research report on Tuesday, November 1st. Barclays raised their price objective on shares of Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 18th. Wells Fargo & Company raised their price objective on shares of Gilead Sciences from $75.00 to $90.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 3rd. Finally, Argus raised their price objective on shares of Gilead Sciences from $70.00 to $100.00 in a research report on Wednesday, November 9th. Nine investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $87.40.

Insider Transactions at Gilead Sciences

In other news, CAO Diane E. Wilfong sold 6,416 shares of the firm’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $83.50, for a total value of $535,736.00. Following the sale, the chief accounting officer now owns 28,333 shares in the company, valued at $2,365,805.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CAO Diane E. Wilfong sold 16,255 shares of the firm’s stock in a transaction on Tuesday, November 1st. The stock was sold at an average price of $79.25, for a total value of $1,288,208.75. Following the completion of the transaction, the chief accounting officer now directly owns 28,333 shares of the company’s stock, valued at $2,245,390.25. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Diane E. Wilfong sold 6,416 shares of the firm’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $83.50, for a total value of $535,736.00. Following the completion of the transaction, the chief accounting officer now directly owns 28,333 shares of the company’s stock, valued at $2,365,805.50. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Up 0.9 %

Shares of Gilead Sciences stock opened at $84.02 on Wednesday. The company’s fifty day simple moving average is $85.92 and its 200-day simple moving average is $73.22. The company has a market cap of $105.38 billion, a price-to-earnings ratio of 31.71, a PEG ratio of 0.80 and a beta of 0.45. The company has a current ratio of 1.30, a quick ratio of 1.16 and a debt-to-equity ratio of 1.14. Gilead Sciences, Inc. has a 1 year low of $57.17 and a 1 year high of $89.74.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.44 by $0.46. The business had revenue of $7.04 billion for the quarter, compared to the consensus estimate of $6.12 billion. Gilead Sciences had a net margin of 12.29% and a return on equity of 38.51%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.08 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 29th. Stockholders of record on Thursday, December 15th were paid a $0.73 dividend. The ex-dividend date of this dividend was Wednesday, December 14th. This represents a $2.92 annualized dividend and a dividend yield of 3.48%. Gilead Sciences’s payout ratio is 110.19%.

Gilead Sciences Company Profile

(Get Rating)

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.